1-4 of 4
David B. Miklos
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11

Open Access
Michael D. Jain, David B. Miklos, Caron A. Jacobson, John M. Timmerman, Jennifer Sun, Jenny Nater, Xiang Fang, Ankit Patel, Madison Davis, Darren Heeke, Tan Trinh, Mike Mattie, Frank Neumann, Jenny J. Kim, Christina To, Simone Filosto, Ran Reshef
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (20): 4118–4127.
https://doi.org/10.1158/1078-0432.CCR-23-0916
Published: 13 October 2023
View article titled, Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11
Open the PDF for Axicabtagene Ciloleucel in Combination with the 4–1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11 in another window
Includes: Supplementary data
Journal Articles

Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma

Open Access
Jason R. Westin, Frederick L. Locke, Michael Dickinson, Armin Ghobadi, Mahmoud Elsawy, Tom van Meerten, David B. Miklos, Matthew L. Ulrickson, Miguel-Angel Perales, Umar Farooq, Luciano Wannesson, Lori Leslie, Marie José Kersten, Caron A. Jacobson, John M. Pagel, Gerald Wulf, Patrick Johnston, Aaron P. Rapoport, Linqiu Du, Saran Vardhanabhuti, Simone Filosto, Jina Shah, Julia T. Snider, Paul Cheng, Christina To, Olalekan O. Oluwole, Anna Sureda
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (10): 1894–1905.
https://doi.org/10.1158/1078-0432.CCR-22-3136
Published: 15 May 2023
View article titled, Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
Open the PDF for Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET

Free
Federico Simonetta, Israt S. Alam, Juliane K. Lohmeyer, Bita Sahaf, Zinaida Good, Weiyu Chen, Zunyu Xiao, Toshihito Hirai, Lukas Scheller, Pujan Engels, Ophir Vermesh, Elise Robinson, Tom Haywood, Ataya Sathirachinda, Jeanette Baker, Meena B. Malipatlolla, Liora M. Schultz, Jay Y. Spiegel, Jason T. Lee, David B. Miklos, Crystal L. Mackall, Sanjiv S. Gambhir, Robert S. Negrin
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (4): 1058–1068.
https://doi.org/10.1158/1078-0432.CCR-20-2770
Published: 15 February 2021
View article titled, Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET
Open the PDF for Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET in another window
Includes: Supplementary data
Journal Articles

A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation

Free
Sally Arai, Joseph Pidala, Iskra Pusic, Xiaoyu Chai, Samantha Jaglowski, Nandita Khera, Jeanne Palmer, George L. Chen, Madan H. Jagasia, Sebastian A. Mayer, William A. Wood, Michael Green, Teresa S. Hyun, Yoshihiro Inamoto, Barry E. Storer, David B. Miklos, Howard M. Shulman, Paul J. Martin, Stefanie Sarantopoulos, Stephanie J. Lee, Mary E.D. Flowers
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2): 319–327.
https://doi.org/10.1158/1078-0432.CCR-15-1443
Published: 14 January 2016
View article titled, A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation
Open the PDF for A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation in another window
Includes: Supplementary data